A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.

NCT01863771 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

DRUG: Golimumab
OTHER: Placebo

Sponsor

Janssen Pharmaceutical K.K.